Pfizer

Oncology Research and Development Postdoctoral Program

Robert T. Abraham, Ph.D.
Senior Vice-President and
Group Head, ORD
Mentor, Pfizer WRD Postdoctoral Program

Education

Undergraduate: B.S., Biology/Chemistry, Bucknell University
Graduate: Ph.D., Pharmacology, University of Pittsburgh
Postdoctoral Training: Mayo Clinic

Research Interests:

I have been continuously involved in graduate and postgraduate education during my entire career in both academia and the pharmaceutical industry. My long-standing research interests encompass the broad areas of cancer cell biology, and cancer cell signaling and metabolism.  Current research activities are focused on the interplay among the PI-3 kinase-mTOR pathway, glutamine metabolism, and the autophagic machinery.

Selected Publications

Rejto PA and Abraham RTMTOR mutations in the crosshairs of targeted therapy.  Cancer Discovery 4, 513-515 (2014).

Shanware NP, Bray K, Abraham RT. The PI3K, metabolic, and autophagy networks: Interactive partners in cellular health and disease. Annu. Rev. Pharmacol. Toxicol. 53, 89-106 (2013).

Eng CH, Yu K, Lucas J, White E, and Abraham RTAmmonia derived from glutaminolysis is a diffusible regulator of autophagy.  Science Signaling 3, 1-9 (2010).

Yu K, Shi C, Toral-Barza L, et al. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Research 70, 621-31 (2010).